Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Fuzuloparib by Jiangsu Hengrui Medicine for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Fuzuloparib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction....